Upstream therapies to prevent atrial fibrillation
Why the study?
Do upstream therapies (such as ACEI, ARB, statins) prevent atrial fibrillation in patients with cardiovascular risk factors?
Population
Patients at risk of atrial fibrillation, including those with hypertension or heart failure
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Insufficient evidence precludes routine upstream therapy for AF prevention; leaves open potential benefit pending large randomized trials.
Structured PICO
Do upstream therapies (such as ACEI, ARB, statins) prevent atrial fibrillation in patients with cardiovascular risk factors?
P
Population
Patients at risk of atrial fibrillation, including those with hypertension or heart failure
I
Intervention
Upstream therapies targeting atrial remodelling (e.g., ACE inhibitors, angiotensin receptor blockers, statins, steroids, and N-3 polyunsaturated fatty acids)
O
Outcome
Prevention of atrial fibrillation
Upstream therapies such as ACE inhibitors and ARBs show promise for preventing atrial fibrillation, particularly in patients with hypertension or heart failure, but broader application requires confirmation from ongoing large-scale trials.
Cite This Study
Dorian et al. (2008) studied this question.